Literature DB >> 3021501

A 4-week Australian multicentre study of nedocromil sodium in asthmatic patients.

R Ruffin, J H Alpers, D K Kroemer, A R Rubinfeld, M C Pain, D Czarny, G Bowes.   

Abstract

The use of nedocromil sodium 4 mg q.i.d. in asthmatics with mildly unstable asthma induced by a reduction of their inhaled beclomethasone dipropionate dose was investigated in a double-blind, parallel group, placebo-controlled study. Compared with placebo, nedocromil sodium improved night-time and daytime asthma score, night-time and daytime bronchodilator use, and evening PEFR at some stage during the 4-week treatment. It is concluded that nedocromil sodium exerts a beneficial effect in chronic asthma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3021501

Source DB:  PubMed          Journal:  Eur J Respir Dis Suppl        ISSN: 0106-4347


  4 in total

Review 1.  Nedocromil sodium. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of reversible obstructive airways disease.

Authors:  J P Gonzalez; R N Brogden
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

2.  Early use of inhaled nedocromil sodium in children following an acute episode of asthma.

Authors:  A M Edwards; J Lyons; E Weinberg; F Weinberg; J D Gillies; G Reid; C F Robertson; P Robinson; M Dalton; P Van Asperen; C Wilson; J Mullineux; A Mullineux; P D Sly; M Cox; A F Isles
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

Review 3.  Nedocromil sodium for chronic asthma in children.

Authors:  A V Sridhar; M McKean
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

4.  Corticosteroid-sparing effect of chromoglycate sodium and nedocromil.

Authors:  A F Capristo; M M Del Giudice; C Alfaro; N Maiello
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.